The kinome, cyclins and cyclin-dependent kinases of pituitary adenomas, a look into the gene expression profile among tumors from different lineages

• Main Authors: Keiko Taniguchi-Ponciano (Author), Lesly A. Portocarrero-Ortiz (Author), Gerardo Guinto (Author), Sergio Moreno-Jimenez (Author), Erick Gomez-Apo (Author), Laura Chavez-Macias (Author), Eduardo Peña-Martínez (Author), Gloria Silva-Román (Author), Sandra Vela-Patiño (Author), Jesús Ordoñez-García (Author), Sergio Andonegui-Elguera (Author), Aldo Ferreira-Hermosillo (Author), Claudia Ramirez-Renteria (Author), Etual Espinosa-Cardenas (Author), Ernesto Sosa (Author), Ana Laura Espinosa- (Author), Latife Salame-Khouri (Author), Carolina Perez (Author), Blas Lopez-Felix (Author), Guadalupe Vargas-Ortega (Author), Baldomero Gonzalez-Virla (Author), Marcos Lisbona-Buzali (Author), Daniel Marrero-Rodríguez (Author), Moisés Mercado (Author)
• Format: Book
• Published: BMC, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.1186/s12920-022-01206-y; 1755-8794
• Keywords: Pituitary adenoma; Kinome; Cyclin; Cyclin-dependent kinase; Cell cycle; Pituitary tumors; Internal medicine; RC31-1245; Genetics; QH426-470
• Source: BMC Medical Genomics, Vol 15, Iss 1, Pp 1-12 (2022)

Abstract Background Pituitary adenomas (PA) are the second most common intracranial tumors and are classified according to hormone they produce, and the transcription factors they express. The majority of PA occur sporadically, and their molecular pathogenesis is incompletely understood. Methods Here we performed transcriptome and proteome analysis of tumors derived from POU1F1 (GH-, TSH-, and PRL-tumors, N = 16), NR5A1 (gonadotropes and null cells adenomas, n = 17) and TBX19 (ACTH-tumors, n = 6) lineages as well as from silent ACTH-tumors (n = 3) to determine expression of kinases, cyclins, CDKs and CDK inhibitors. Results The expression profiles of genes encoding kinases were distinctive for each of the three PA lineage: NR5A1-derived tumors showed upregulation of ETNK2 and PIK3C2G and alterations in MAPK, ErbB and RAS signaling, POU1F1-derived adenomas showed upregulation of PIP5K1B and NEK10 and alterations in phosphatidylinositol, insulin and phospholipase D signaling pathways and TBX19-derived adenomas showed upregulation of MERTK and STK17B and alterations in VEGFA-VEGFR, EGF-EGFR and Insulin signaling pathways. In contrast, the expression of the different genes encoding cyclins, CDK and CDK inhibitors among NR5A1-, POU1F1- and TBX19-adenomas showed only subtle differences. CDK9 and CDK18 were upregulated in NR5A1-adenomas, whereas CDK4 and CDK7 were upregulated in POUF1-adenomas. Conclusions The kinome of PA clusters these lesions into three distinct groups according to the transcription factor that drives their terminal differentiation. And these complexes could be harnessed as molecular therapy targets.